<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688766</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-504-06</org_study_id>
    <nct_id>NCT00688766</nct_id>
  </id_info>
  <brief_title>Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib</brief_title>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of IPI-504 in Patients With Metastatic and/or Unresectable GIST Following Failure of at Least Imatinib and Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Infinity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      IPI-504-06 is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to&#xD;
      evaluate the efficacy and safety of IPI-504 as compared to placebo in patients with&#xD;
      metastatic and/or unresectable GIST following failure of at least imatinib and sunitinib.&#xD;
&#xD;
      Approximately 195 patients will be randomized using a 2:1 ratio to receive either IPI-504&#xD;
      (N=130) or placebo (N=65). Upon unblinding, patients receiving either IPI-504 or placebo may&#xD;
      receive IPI-504 in the open-label portion of the study if defined inclusion criteria are met.&#xD;
&#xD;
      Early and frequent imaging timepoints (Weeks 2, 5, 8, 14 and every 6 weeks thereafter) are&#xD;
      incorporated into this study to capture progression events and limit patient exposure to&#xD;
      ineffective agents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on Independent Data Monitoring Committee (IDMC) recommendation.&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the progression free survival (PFS) in both study arms</measure>
    <time_frame>Multiple timepoints</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the disease control rate (DCR) in both arms</measure>
    <time_frame>Multiple timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the time to progression (TTP) in both arms</measure>
    <time_frame>Multiple timepoints</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the overall survival (OS) in both arms</measure>
    <time_frame>Continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of IPI-504 in this patient population</measure>
    <time_frame>Signing of the informed consent to 30 days after discontinuation of drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>IPI-504</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>retaspimycin hydrochloride (IPI-504) plus best supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus best supportive care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retaspimycin hydrochloride (IPI-504)</intervention_name>
    <description>IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.</description>
    <arm_group_label>IPI-504</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best supportive care</intervention_name>
    <description>Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.</description>
    <arm_group_label>IPI-504</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age at the time of study randomization.&#xD;
&#xD;
          -  Histologically confirmed metastatic and/or unresectable GIST.&#xD;
&#xD;
          -  Measurable disease on CT or MRI as defined by RECIST.&#xD;
&#xD;
          -  Documented radiographic progression or intolerance to imatinib and sunitinib.&#xD;
&#xD;
          -  Clinical failure of the most recent prior therapy for GIST. Note: There is no limit to&#xD;
             the number of prior therapies a patient may have received.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1.&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL (80 g/L).&#xD;
&#xD;
          -  Absolute Neutrophil Count ≥ 1500/µL (1.5 x 109/L).&#xD;
&#xD;
          -  Platelets ≥ 100,000 /µL (100 x 109/L).&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 x upper limit of normal (ULN), or ≤ 5.0 x ULN if considered&#xD;
             secondary to liver metastases.&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN, or ≤ 5.0 x ULN if considered secondary to liver&#xD;
             metastases.&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN.&#xD;
&#xD;
          -  PT and PTT ≤ 1.5 x ULN unless the patient is receiving warfarin. If the patient is&#xD;
             receiving warfarin, the INR must be within therapeutic range.&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous administration of other known heat shock protein 90 (Hsp90) inhibitors.&#xD;
&#xD;
          -  Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable&#xD;
             disease.&#xD;
&#xD;
          -  Initiation or discontinuation of concurrent medication that is a potent CYP3A&#xD;
             inhibitor less than 2 weeks prior to administration of IPI-504 or placebo.&#xD;
&#xD;
          -  History of any of the following within the last 6 months: cardiac disease such as&#xD;
             acute coronary syndrome or unstable angina, symptomatic congestive heart failure,&#xD;
             uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or any&#xD;
             other significant co-morbid condition or disease which, in the judgment of the&#xD;
             investigator, would place the patient at undue risk or interfere with the study.&#xD;
&#xD;
          -  Grade 3 or 4 hemorrhagic event within the last 6 months.&#xD;
&#xD;
          -  Known human immunodeficiency virus positivity.&#xD;
&#xD;
          -  Sinus bradycardia (resting heart rate &lt; 50 bpm) secondary to intrinsic conduction&#xD;
             system disease.&#xD;
&#xD;
          -  QTcF ≥ 470 milliseconds, or previous history of clinically significant QTc&#xD;
             prolongation while taking other medications.&#xD;
&#xD;
          -  History of prior malignancies within the past 3 years other than non-melanomatous skin&#xD;
             cancers that have been controlled, prostate cancer that has been treated and has not&#xD;
             recurred, non-muscle-invasive bladder cancer, and carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Active or recent history (within 3 months) of keratitis or keratoconjunctivitis&#xD;
             confirmed by ophthalmology or optometry exam.&#xD;
&#xD;
          -  Presence of Left Bundle Branch Block, Right Bundle Branch Block plus left anterior&#xD;
             hemiblock, bifascicular block, or 3rd degree heart block. This does not include&#xD;
             patients with a history of these events with adequate control by pacemaker.&#xD;
&#xD;
          -  Known CNS metastases.&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Santabarbara, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Infinity Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Demetri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.gistsupport.org</url>
    <description>Gist Support International - Patient Advocacy Group</description>
  </link>
  <link>
    <url>http://www.liferaftgroup.org</url>
    <description>The Liferaft Group - Patient Advocacy Group</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <disposition_first_submitted>December 6, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 6, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 10, 2012</disposition_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>Metastatic and/or Unresectable Gastrointestinal Stromal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

